suppressive drug therapy such as zidovudine. Drug-induced neutropenia and immune thrombocytopenia are also frequent and occur in up to 50% of acquired immunodeficiency syndrome (AIDS) patients. Attempts to reduce the impact of bone marrow failure have focused on dose reduction of zidovudine, ganciclovir, and chemotherapy, and the use of recombinant hematopoietic hormones such as erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF).
Despite these maneuvers, approximately 30% of patients with AIDS receiving ridovudine will become transfusiondependent. This has led to investigations of other cytokines that may increase blood cell formation. The recent identification of decreased number and proliferation of hematopoietic YTOPENIAS and poor hematopoietic tolerance of C myelosuppressive therapy are common complications of human immunodeficiency virus (HIV) infection. Of these complications, anemia is the most common. Approximately 10% of HIV-infected individuals will be anemic at initial clinical presentation and greater than 70% of patients will develop anemia at some time during their disease course.' Severe anemia is a cause of significant morbidity from the lack of exercise tolerance and decreased work capacity. Moreover, treatment of severe anemia by transfusion uses scarce renewable resources, may increase immunosuppression already present in the patient? and exposes the patient to further infectious complications: Neutropenia and immune thrombocytopenia are also frequently seen. Severe neutropenia and thrombocytopenia can limit the ability of the patients to receive antiretroviral therapy and often limits their tolerance of myelosuppressive chemotherapy for acquired immunodeficiency virus (AIDS)-related cancers. Recent studies have shown that recombinant granulocyte colony-stimulating factor (G-CSF)" and granulocyte-macrophage CSF (GM-CSF) can ameliorate the neutropenia of HIV infection in patients, but thrombocytopenia continues to be a significant clinical problem.
progenitors in patients with HIV infection suggests that agents which have activity on progenitor cell pools may have clinical utility. We demonstrate that human stem cell factor (HuSCF) increases burst-forming unit-erythroid (BFU-E), colony-forming unit-granulocyte-monocyte (CFU-GM), and CFUMix formation in vitro in normal and HIV-infected individuals. HuSCF also decreases the sensitivity of BFU-E to inhibition by zidovudine without altering HIV replication in lymphocytes or monocytes, altering peripheral blood mononuclear cell proliferation to phytohemagglutinin (PHA) and interleukin-2 (IL-2) or altering the effectiveness of ridovudine or dideoxyinosine in inhibiting HIV replication in lymphocytes or monocytes. These studies suggest that HuSCF may have clinical utility in HIV infection as an adjunctive treatment for HIV-related cytopenias. o 1991 by The American Society of Hematology.
Multiple abnormalities have been identified in patients with HIV infection that may lead to the development of anemia and other cytopenias. These include autoantibodies and malnutrition, as well as defects in the proliferative capacities of hematopoietic progenitors?" The defects in the hematopoietic progenitors are multilineage and include decreased proliferative capacities of granulocyte/monocyte progenitors (colony-forming unit-granulocyte-monocyte The drug that is the most frequent cause of HIV-related anemia is zid~vudine.~,'~ Depending on the dose of zidovudine used and the stage of HIV infection being treated, the fraction of patients with anemia requiring transfusion ranges from 1.5% to 33%.'2v'4.15 However, given zidovudine's ability to decrease the incidence of opportunistic infections" and improve long-term survival,16 finding therapeutic options other than transfusion for zidovudine-induced anemia is important.
One drug, erythropoietin (EPO), reduced RBC transfusions and increased hemoglobin values in patients receiving zidovudine in placebo-controlled, double-blind studies." Meta-analysis of four placebo-controlled trials showed that patients treated with EPO benefitted from drug therapy regardless of dose used and route of administration.18 The beneficial effects of EPO were principally limited to those patients with baseline erythropoietin levels less than 500 U/mL. Despite the success of EPO as a single agent, as many as 25% to 50% of patients with severe HIV infection who receive EPO will not achieve a significant increase in hemoglobin while receiving ~i d o v u d i n e .~~, '~~'~ The failure to correct severe HIV-related anemia with EPO has led to studies of additional cytokines that may be active in e~ythropoiesis.'~~'~~~~ The identification by several groups of the markedly impaired proliferation of early RBC progenitors (BFU-E)"." and inhibition of these RBC progenitors by low doses of zid~vudine'~~'~ suggest that cytokines which either increase RBC progenitor formation or alter the effect of zidovudine on these early progenitors may be clinically useful.
Human stem cell factor (HuSCF) is a glycosylated cytokine produced by bone marrow stroma and other cells, which directly stimulates primitive pluripotent human bone marrow progenitor When used in conjunction with EPO in vitro, HuSCF results in a marked increase in BFU-E formation." The burst colonies are larger and more dense in cell number than those seen with EPO alone. Preliminary in vivo studies of HuSCF in primates suggests that the increase in BFU-E formation observed in vitro is responsible for the increase in hemoglobin that was observed. The pluripotent nature of the progenitor cell proliferation may explain the increases seen in other lineages as well.
Because of the activity of HuSCF on early RBC progenitors, we investigated the effect of purified, Escherichia coli-derived, HuSCF on blood cell progenitors in the bone marrow and peripheral blood of patients with HIV infection. We compared these results in HIV-infected patients with those in normal subjects. We also examined the capacity of HuSCF to alter the inhibitory effect of zidovudine on RBC progenitors.
MATERIALS AND METHODS
Source and preparation of peripheral blood mononuclear cells. Leukopaks were obtained from HIV-, cytomegalovirus (CMV)-, and Epstein-Barr virus (EBV)-seronegative normal donors from the American Red Cross. Peripheral blood was obtained from six patients with HIV infection after informed consent was obtained. Two patients were asymptomatic, one had AIDS-related complex, and three had AIDS. None of the six patients had received zidovudine within the last 6 months. None of the patients were anemic (hemoglobin < 13.5 g/dL) at the time of study. In addition, bone marrow was obtained from three patients with HIV infection and multiple cytopenias in the absence of drug therapy. Morphologic examination of these bone marrows was normal and no infections were found after cultures. Normal bone marrow for controls was obtained from volunteer donors. All studies were conducted in accordance with UCLA Human Subject Protection Committee regulations.
Peripheral blood and bone marrow mononuclear cells were isolated from leukopaks, peripheral blood, and bone marrow using Ficoll-Hypaque sedimentation followed by extensive washing with Hank's Balance Salt Solution (HBSS, GIBCO, Grand Island, NY).
Blood cells were enumerated and viability ascertained by trypan blue dye exclusion.
BFU-EAssay. Assays for BFU-E were performed in a standard protocol using normal human bone marrow as the control. Heparinized blood was diluted with an equal volume of HBSS, layered over Ficoll-Paque (Pharmacia, Piscataway, NJ), and centrifuged at 400 x g for 30 minutes at room temperature. Light density cells (specific gravity [sg], < 1.077) were collected and washed twice in HBSS. Cells were resuspended in Iscove's Medium with 10% fetal bovine serum (GIBCO) at a concentration of 1 x 107/mL. Cells (1 x lo5) were cultured in Iscove's Medium supplemented with 5 x lo-' mol/L 2-Mercaptoethanol(2ME) (Sigma Chemicals, St Louis, MO), 30% fetal bovine serum, and either 1 or 4 IU of human recombinant EPO (AmGen, Thousand Oaks, CA) in 0.3% agar. Four concentrations of E coli-derived HuSCF (AmGen)'' were added (0, 10,100, and 1,000 ng/mL). Zidovudine (AZT) was added to the mixture, resulting in final concentrations of 0,O.Ol pmol/L, 0.1 pmol/L, 1.0 pmol/L. BFU-E were scored after 14 days of culture in a humidified atmosphere containing 5% CO,. Each assay was performed in duplicate and colonies with more than 50 cells present on day 14 with hemoglobinization were scored as BFU-E.
The 50% inhibitory concentration for zidovudine was calculated by expressing the mean of four determinations of BFU-E for each level of zidovudine and HuSCF as a percentage of control (no added zidovudine). Linear regression was used to calculate the slope of inhibition. The 50% inhibitory concentration was calculated by interpolation and the value used as the exponent for the base of 10. This results in direct calculation of the IDsv The R Z values for all the slopes were greater than .90.
Assays for CFU-GM and CFUMix were performed in a standard protocol using normal human bone marrow as the control. Mononuclear cells were isolated as above. Cells were resuspended in Iscove's Medium with 10% fetal bovine serum at a concentration of 1 X 107/mL. Cells (1 x l a )
were cultured in Iscove's Medium supplemented with 5 x mol/L 2ME, 30% fetal bovine serum, 100 pmol/L recombinant human GM-CSF (AmGen), and, in the case of CFU-Mix, 1 IU of human recombinant EPO in 0.3% agar. Four concentrations of E coli-derived HuSCF were added (0, 10, 100, and 1,OOO ng/mL). CFU-GM and CFU-Mix were scored using standard criteria for colonies after 10 days of culture in a humidified atmosphere containing 5% CO,. Each assay was performed in duplicate.
The effects of HuSCF interleukin-3 (IL-3), GM-CSF, G-CSF, EPO, and M-CSF were evaluated on both peripheral blood lymphocytes depleted of the adherent monocyte fraction and the isolated adherent monocyte fraction of the same preparation.
In brief, the peripheral blood mononuclear cell fraction was isolated from leukopaks as above. Flasks were precoated with human AB sera (Irvine Scientific, Irvine, CA) and the peripheral blood mononuclear cells were allowed to adhere for 2 hours at 3PC. The supernatant cells were gently removed and resuspended in complete media (RPMI-1640 with 1% penicillin, streptomycin [penn/strep] and 20% fetal bovine serum) containing 1.0% phytohemagglutinin (PHA) for 48 hours. The supernatant cells were washed and resuspended in Iscove's modified Dulbecco's media (IMDM) with pendstrep, 10% fetal bovine serum, and 10 U/mL of IL-2 (AmGen). This population of cells was greater than 90% CD3+. The adherent cell fraction was gently washed with phosphatebuffered saline (PBS, Irvine Scientific) and the cells were resuspended in IMDM with penn/strep, 15% fetal bovine serum, and 5% human AB sera. The monolayer of cells were incubated for 5 days at 37°C in a 5% CO, humidified atmosphere. Routine analysis of these cell populations after 72 hours showed that a nonadherent cell fraction contained less than 5% monocytes and the adherent cell fraction contained greater than 95% monocytes/macrophages (as determined by flow cytometry using Leu-M3 antibody).
Two cloned isolates of HIV with different target cell HIV,,,,, and HIV,,.,, were used in these studies. The HIV,,.,, strain was used for infection of peripheral blood lymphocytes. For these studies, 72-hour PHA and IL-2-stimulated nonadherent mononuclear cells were washed and resuspended in fresh media after counting and trypan blue dye exclusion. The cells were exposed to the cytokines at the following concentrations: G-CSF, 10, 100, and 500 pmol/L; GM-CSF (Sandoz, East Hanover, NJ), CFU-GM and CFU-Mix assays.
Effects of cytokines on HIV viral replication.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From 3202 10, 100, and 500 pmol/L; IL-3, 10, 100, and 500 pmol/L; M-CSF (Genetics Institute, Cambridge, MA), 0.01, 0.1, and 1.0 ng/mL; EPO, 1,4, and 10 U/mL; and HuSCF, 20,200, and 1,000 ng/mL. The cultures were subsequently inoculated with 100 TCID,, of HIV,R.ap The supernatant media was assayed on days 3,7,10, and 14 for HIV p24 antigen production by enzyme-linked immunosorbent assay (ELISA, Abbott Laboratories, Abbott Park, IL).
For the monocyte assays, the adherent cell fraction was gently removed using PBS and vigorous washing. Cells were counted and cell viability determined by trypan blue exclusion. Cells were replated at 1 x 106/mL of media and exposed to 100 TCID,, of HIV,,, and the appropriate concentration of cytokine. Supernatant media was checked on days 3, 7, 10, and 14 for HIV p24 antigen production as above. The assays were performed in duplicate and repeated with four different donor cells.
Effects of HuSCF on HIV inhibition by dideoxynucleoside analogues. Partially purified monocyte and lymphocyte fractions were obtained as above. Cells were exposed to zidovudine (AZT, Burroughs Wellcome, Triangle Park, NC) and dideoxyinosine (ddI) (Sigma Chemicals) at concentrations of loF5 to lo-* mol/L. HuSCF was added at concentrations of 0, 10, and 100 ng/mL and HIV p24 antigen production was monitored on days 3 to 14 by HIV p24 antigen ELISA as above. Assays were performed in duplicate and the experiments repeated twice with four different donor cells.
Effects of HuSCF on stimulated peripheral blood mononuclear celh. Peripheral blood mononuclear cells were isolated from the leukopaks of two additional normal donors as described above. Cells were resuspended in IMDM containing 20% fetal bovine serum, penn/strep, 1.0% PHA, and 10 U/mL of IL-2. Four concentrations of HuSCF (0, 10, 100, 1,000 ng/mL) were added to the media. Complete lymphocyte subset analysis of cellular antigens were analyzed in duplicate by two color fluorescent cytometry on days 0, 3, 7, and 10. Differences in percentages of cell populations were detected using independent and paired t-tests (two-tailed). Comparisons were made between drug-treated and non-drug-treated values for a single-day and between-single-day values and baseline. Cytometric analysis was performed in duplicate.
In separate experiments, mononuclear cells were isolated as above and stained with Leu-M3, Leu-3, Leu-2, Leu-4 and a monoclonal antibody SR-1 specific for human c-kit antigen (gift of Virginia Brody, University of Washington, Seattle, WA). Multicolor flow cytometry was performed and cell populations enumerated after selection of lymphocyte and monocyte windows. 
RESULTS
Exposure of peripheral blood mononuclear cells to EPO and HuSCF resulted in a dose-dependent increase in BFU-E formation in the two normal patients studied ( Fig  1A) . Significant increases (up to 100%) were seen with concentrations of HuSCF between 10 and 1,000 ng/mL. Near maximal activity was seen at 10 ng/mL, suggesting that lower concentrations may be active. There were significant increases in BFU-E when the dose of EPO was increased from 1 IU to 4 IU/mL (Fig 1B) . The colonies observed were significantly larger in size than the bursts seen in the absence of HuSCF (Fig 2) .
In the six HIV-infected individuals studied, significant dose-dependent increases in BFU-E were also seen with HuSCF treatment (Fig 3) . Although the number of BFU-E in the absence of HuSCF was markedly reduced compared with normal (range, 2 to 26 BFU-E/lOS peripheral blood mononuclear cells compared with -74 BFU-E/105 for normals), the percentage increases in BFU-E were significantly higher in the HIV-infected individuals. Near normal numbers of BFU-E were obtained for two individuals at the 1,000 ng/mL concentration of HuSCF. Although the absolute number of BFU-E seen for some of the patients was still well below normal, all six individuals responded in vitro to HuSCF.
HuSCF also increased CFU-GM and CFU-Mix in patients with AIDS (Table l) . The magnitude of increase in CFU-GM in patients with AIDS was smaller than that observed in the normals, but the basal number of CFU-GM varied up to 1 log in the three patients examined. Some patients had a 10-fold increase in CFU-GM/2 x lo5 (cells) at baseline compared with the normals. This may be a result of patient selection, as these patients were cytopenic in the absence of drug therapy. Increases in CFU-Mix similar to the increases in CFU-GM were seen.
Because previous studies showed that cytokines could alter the intracellular uptake or intracellular metabolism of deoxynucleosides,24 we evaluated the capacity of HuSCF to modulate the inhibition of red cell progenitors by zidovu-
:oncentration of Zidovudine dine. Each of the normals and all of the HIV individuals had BFU-E assays performed in the presence and absence of three concentrations of zidovudine and four concentrations of HuSCF. As shown (Figs 1 and 2 ), the addition of HuSCF markedly reduced inhibition of early RBC progenitors by zidovudine. Significant alterations in the 50% inhibitory dose of zidovudine for BFU-E was seen at all three concentrations of HuSCF for the normal subjects. The IC,, (50% inhibitory concentration) ranged from 2.65 to 1,376 ymol/L of zidovudine ( Table 2 ). All three of these inhibitory concentrations of zidovudine are well above normal serum levels obtained after 1,000 mg/d of zidovudine." Similar results were observed for all six individuals infected with HIV. However, because of the few number of RBC progenitors in two of the patients, the increases in the ID,, of zidovudine for BFU-E did not reach statistical significance for the group of HIV-infected patients. Nonetheless, the same trends were present and replicated the effects of HuSCF on BFU-E in the presence of zidovudine in the normal individuals. Because other cytokines have been shown to alter the replication of HIV in either primary monocytes or lymphocytes,26-28 we examined the effect of HuSCF on HIV replication of cloned HIV isolates in semipure populations of peripheral blood lymphocytes and monocytes. Using the HIV,,,, isolate, which is monocytotropi~,~~ and three concentrations of six different cytokines, we found that HuSCF has no effect on virus replication in primary human monocytes exposed to HIV,,,, (Table 3 ). In contrast, statistically significant increases in virus HIV p24 antigen production in the cell supernatant were observed for IL-3 and GM-CSF (P < .01 for both IL-3 and GM-CSF, independent t test [two-tailed]). Recombinant EPO and G-CSF had no effect on virus replication in monocytes at the levels tested. M-CSF increased HIV replication only slightly, although there were striking morphologic changes in the M-CSFtreated cultures. The modest effects of M-CSF in this system have been previously reported and may be characteristic of this monocytotropic HIV isolate.26 The alterations in virus replication by IL-3 are best illustrated by observing the time course of HIV antigen production in these cells (Fig 4) . As shown, IL-3, but not HuSCF, increases virus replication in human mononuclear cells in a time-and dose-dependent manner. In fact, HuSCF actually reduced virus antigen production. Similar HIV-replicative enhanc- The I D, , for BFU-E for each level of HuSCF was calculated as described in the text. The values represent the mean for the two normal donors. Representative levels of HIV p24 antigen production (in pg/mL) on day 10 after infection are presented for each of the six cytokines at the four doses of each cytokine used. The assays were performed in duplicate in two different donor monocytes and lymphocytes and repeated. The values are the mean of duplicates for two different donor monocytes. Only GM-CSF and IL-3 significantly increased HIV p24 antigen production (independent t-test, two-tailed, P < .05).
ing effects were seen with GM-CSF in these primary monocytes (Table 3) . We also examined the capacity of five cytokines to alter the replication of a T-cell trophic HIV isolate, HIV,,,,F in primary peripheral blood lymphocytes. None of the five cytokines tested (EPO, G-CSF, GM-CSF, IL-3, and HuSCF) showed any significant increase in HIV p24 antigen production at any of the three concentrations of each cytokine used (Table 3) .
Previous studies have shown that GM-CSF may enhance the antiviral efficacy of zidovudine in peripheral blood mononuclear cell fractions by altering zidovudine uptake and intercellular levels of thymidine triph~sphate.'~ We examined the capacity of HuSCF to modulate the in vitro antiviral efficacy of two dideoxynucleoside analogues, zidovudine and ddI. Using peripheral blood primary monocytes and lymphocytes and the two previously described strains of HIV, we were unable to demonstrate any effect of HuSCF on the inhibitory activity of zidovudine or ddI (Table 4) . Complete suppression of HIV,,.,, and HIV,,.,,, replication in lymphocytes and monocytes were seen at the mol/L concentration of zidovudine. There was no alteration in this inhibition with up to 100 ng/mL of HuSCF. Similarly, ddI completely inhibited HIV p24 antigen production from peripheral blood monocytes and lymphocytes exposed to HIVJ,.FL and HIV,,.,,,, respectively, at concentrations of mol/L. There was no significant increase in HIV p24 antigen production at concentrations up to 100 ng/mL of HuSCF.
We also examined the capacity of HuSCF to alter specific subset proliferation in peripheral blood mononuclear cells exposed to PHA and IL-2. Using normal peripheral blood mononuclear cells from two donors and exposing these cells to PHA and IL-2, we sequentially studied lymphocyte marker populations of tac+ and tac-subpopulations on days 0, 3, 7, and 10 after exposure to HuSCF. Although significant changes in T-cell activation antigens (tac+, (Table 5 ) demonstrated no additional significant alteration in lymphocyte subpopulations examined by exposure to HuSCF up to 1,000 ng/mL for 10 days.
In preliminary studies, we have enumerated and identified the distribution of the receptor for HuSCF using the SR-1 antibody for c-kit on unstimulated circulating mononuclear cell preparations. We found that approximately 2% of circulating peripheral blood CD3+ cells were positive for SR-1 staining. Similarly, using SR-1 and the lymphocyte window, approximately 98% were CD3+. Thus, the majority of SR-1' cells in the circulation are CD3+, but this is only a small population of the CD3+ population. Using threecolor flow cytometry with Leu-2 (CD4) and Leu3 (CD8) marker antibodies, we found that there was a 5050 split of Semipure populations of lymphocytes and monocytes were infected with HIVJccsr and HI V, , , , after exposure to zidovudine (Ai37 or dideoxyinosine (ddl) at concentrations from 10-8 to 10'' mollL. The values represent the mean of four determinations of HIV p24 antigen detected in the supernatant on day 10. Control lymphocytes not exposed to nucleosides had >2,000 p g h L of HIV at the same time point. Control monocytes not exposed to nucleosides had 935 p g h L at the same time point. All values are different from the controls, indicating >90% suppression of virus replication. However, the 10 and 100 ng/mL concentration SCF values are not different from the 0 ng/mL values.
the CDJ'/SR-l+ into CD4' and CD8'. Thus, approximately 1% of circulating lymphocytes are CD3+/CD4+/ SR-1' and approximately 1% are CD3'/CDS+/SR-l+. There were no SR-1 +/Leu-M3+ cells in the lymphocyte window.
Setting the gate on the monocyte population, we found no cells that stained simultaneously with Leu-M3 and SR-1. Thus the majority of SR-I+ cells in the circulation are CD3' and not Leu-M3'. There were no SR-l'/CD3' cells in the monocyte window.
DISCUSSION
Hematopoietic failure and poor tolerance of myelosuppressive therapy are significant problems in patients with HIV infection. Various approaches have been used to reduce the incidence of neutropenia and anemia, including the use of G-CSF, GM-CSF, and EPO'2.'7.'R or altered concentrations of marrow suppressive drugs." Despite the reduction of zidovudine doses over the last year,lSR and the introduction of recombinant EPO into clinical use, anemia related to HIV illness continues to be a major clinical problem.' Fortunately, the frequency of severe neutropenia with currently used antivirals has been significantly reduced with the use of G-CSF and GM-CSF.'* The recent identification by several groups that patients with HIV have impairment of hematopoietic progenitor cell proliferation in multiple lineages very early after HIV infection' suggests that decreased proliferation of hematopoietic progenitors may be one potential mechanism for the development of cytopenias. HuSCF is a multipotent cytokine that has direct effects on the pluripotent human bone marrow progenitor populations.'z HuSCF may be of benefit to patients whose illness is characterized by decreased numbers and impaired proliferation of human stem cell progenitors such as patients with HIV infection or aplastic anemia.
In this report, we detail the effects of HuSCF on early RBC and WBC progenitors. Exposure to HuSCF in vitro resulted in a dose-and time-dependent increase in RBC and WBC progenitors, and significantly altered the inhibition of RBC progenitors by zidovudine. This was observed in both normal and HIV-infected study populations. HuSCF had no effect on HIV virus replication in primary monocytes or primary human lymphocytes, nor did it alter the efficacy of 2',3',-dideoxynucleoside analogues. This is a significant difference from other cytokines, which have effects on RBC progenitors in vitro, such as IL-3 and GM-CSF. As shown in this and other studies,26,27." both GM-CSF and IL-3 significantly increase replication of HIV in partially purified primary peripheral blood monocytes. These studies suggest that HuSCF may be a good candidate drug for use as adjunctive therapy in the treatment of HIV-related cytopenias. This cytokine appears to directly stimulate human hematopoietic progenitor cells and synergizes with IL-7, G-CSF, GM-CSF, and IL-3 in the production of pre-B lymphocytes, megakaryocytes, monocytes, granulocytes, and mast When HuSCF is used with EPO and GM-CSF in vitro, synergistic increases in early RBC, WBC, and mixed blood cell proliferation are observed. Since the levels of immunoreactive EPO and, in some cases, GM-CSF are elevated in some patients with HIV infection3' and in some patients with zidovudineassociated anemia," administration of HuSCF to these populations could result in significant increases in hemoglobin production in vivo. Use of HuSCF may result in amelioration of HIV-related anemia and may have some activity on the production of WBCs and perhaps platelets.
Stimulation of other progenitor populations for immature lymphocytes, granulocytes, monocytes, and megakaryocytes were not specifically tested in these studies. Since others have shown that human bone marrow progenitors can be infected with HIV in vitro,28 stimulation of HIVinfected progenitors could result in an increase in viral expression and progression of disease. Fortunately, HIV infection of hematopoietic progenitors in vivo appears to be an infrequent e~e n t .~~'~~ Moreover, since HuSCF has no effect on HIV replication in the major sites of HIV infection (mature lymphocytes and monocytes/macrophages), does not alter mature lymphoid proliferation in vitro, and does not alter the efficacy of zidovudine inhibition of HIV replication in vitro in mature lymphocytes or monocytes, HuSCF may be able to increase progenitor pools with a reduced risk of HIV stimulation.
In large part, these later observations may be a result of the restricted expression of c-kit, the receptor for HuSCF. In preliminary studies, c-kit expression appears to be restricted to a small population of cells in mononuclear fractions from peripheral blood bearing the CD3 antigen. This population is evenly split between CD4' and CD8' cells. Monocytes, as identified by the Leu-M3 antigen, do not appear to bear the SR-1 antigen. As a result, mitogenesis or stimulation of HIV replication in these populations by HuSCF is unlikely. Together with the significant stimulation in RBC production observed with HuSCF, these studies suggest that there could be a role for HuSCF as an adjunct to antiretroviral therapy in patients with HIV infection.
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